catalan industry

In Catalonia, direct foreign investment – excluding the stock-exchange –grew by 31.5% year-on-year to reach €3.51 billion in 2013, as indicated by a report from the Spanish Ministry of Economy and Competitiveness. According to the Foreign Investments Registry, with such a figure, Catalonia achieved its second best year in history, only surpassed by the €4.82 billion received in 2010. Besides, Catalonia accounted for 22.2% of all foreign investments in Spain in 2013, which amounted to a total of €15.81 billion, meaning 8.8% more than the previous year. The region of Madrid was the leading Autonomous Community in Spain for foreign investment attraction, receiving €8.64 billion, which is it to say 54.6% of the total amount. However Madrid's sum also represents a 7.1% decrease on 2012 figures.

Greater Barcelona-based car manufacturer Seat has hired 450 new workers to cover an expected increase in production. The new employees will join the workforce at the Martorell factory to aid the production of two of its most popular car models, the Ibiza and the Leon. Seat also announced an increase in overall production during a strong performance in 2013, which saw its highest production rates for 5 years. Besides, the Japanese Nissan recently extended the contract to 308 temporary workers and hired additional 20 people in its Barcelona factory. Last November, Nissan launched a shorter night shift to produce the Primastar X83 van, which was extended in February in order to increase production.

The profits of Catalan pharmaceutical company Grífols in 2013 grew by 34.6% over the previous year, reaching €345.6 million, as reported by the multinational to the Spanish Stock Exchange Regulation Authority (CNMV). The turnover of the company, based in Greater Barcelona, amounted to €2.75 billion, representing a 4.6% increase on 2012 figures. The geographical expansion of the pharmaceutical company has helped mitigating the effects of volatility in currencies, especially between the euro and the dollar. The Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) grew by 9.6% compared to 2012 and stood at €864.6 million, driven by an increase in the sales of plasma proteins and the optimization of the expenses for raw materials and manufacturing.

The management of Barcelona-based Almirall pharmaceutical multinational and trade unions have signed an agreement on Monday, reducing the initially planned number of laid-off employees from 250 to 180. The document, which has mostly been ratified in production and research centres in Greater Barcelona as well as by the marketing network, also provides specific compensations for the workers aged 55 years and over, and the maximum compensations set by the law for the rest of the laid-off staff. According to the General Workers Union (UGT), 30% of the laid-off employees will correspond to voluntary redundancies, which will be proportionally distributed among the different groups of workers.

SITA Ibérica, a Catalan company located in Martorell, close to Barcelona, is one of the fourteen companies to have submitted a petition to destroy 500 tons of chemical weapons from Syria. But the submission was made without the prior knowledge of the Martorell City Council, which opposes the idea to destroy weapons in the Martorell area. The winner of the contest will be announced in early February by the UN body which is responsible for the destruction of the weapons.

In the coming weeks, the management of Volkswagen Group should decide where to produce its latest SUV model, designed in the SEAT Technical Centre in Martorell (Greater Barcelona) and featuring two versions, one for the Catalan brand and the other one for Skoda. The President of the SEAT Workers Committee in Martorell, Matias Carnero, argued that the Catalonia-based factory was the most competitive to produce the vehicle. These past weeks, some sources have asserted that Martorell’s main rival, the Skoda plant in the Czech Republic, would ultimately be chosen. Indeed, it is believed that the President of SEAT Jürgen Stackmann hinted at such a fact in several internal meetings. However, Matias Carnero insisted that the Martorell factory had never been completely ruled out.

The Catalan Government has welcomed the 138 proposals issued by a council of business associations, trade unions, academic experts and leading professionals, who form the so-called ‘Agreement for the Industry’ platform. The President of the Catalan Executive, Artur Mas, stated that those proposals are “a possible seed” for a broader agreement: a National Pact for the Industry that will define the priorities and main guidelines of Catalonia’s industrial policy for the next decade. The Catalan Minister for Business and Employment said that the 138 proposals coincide with “between 70 and 80%” of the Executive’s industrial policies. However he pointed out that the Government couldn’t bring all of them on board for budget or jurisdiction limitations.

Catalan pharmaceutical company Almirall has announced on Tuesday it will buy Aqua Pharmaceuticals, an American company specialised in dermatological treatments. The $328 million transaction reflects the Catalan multinational’s strategy to diversify its activities, by establishing itself in a sector that will be a “key platform for growth”. Aqua Pharmaceuticals has a portfolio of well known brands for treating acne and skin rashes. This year the total sales of the American company’s products are expected to generate $127 million. According to a statement to the National Securities Market Commission (CNMV), Almirall intends to continue employing the same Aqua management team, to benefit from their experience in the U.S. market.

The Catalan pharmaceutical company Grífols and Barcelona’s Alzheimer Treatment&Research Center of Fundació ACE – a family charity – have announced that they will run tests of a vaccine against this neurodegenerative illness from January 2014. It will target 365 Alzheimer’s patients at mild and moderate stages of the illness. The first investigation project that ACE’s centre will host is called Ambar. The 365 participants will be randomly divided into three treatment groups plus a fourth control group. The patients will come from 17 Spanish hospitals and 20 United States’ medical centres. From 1996, the ACE Foundation has evaluated more than 14,000 people, 47% of whom were diagnosed with Alzheimer’s. It has the largest bank of genetic data in Europe.

Samvardhana Motherson Peguform, which produces components and materials to build cars, has announced a €30 million investment in Catalonia, during the business trip of a delegation led by President of the Catalan Government Artur Mas. The Samvardhana Motherson Group, based in Noida, already owns 4 factories in Catalonia, from the former German company Peguform – which was purchased in 2011 by the Indian multinational. €25 million will be invested in rebuilding and enlarging its Polinyà plant, in Greater Barcelona, which produces car paint and was accidentally burned last September. The remaining €5 million will be allocated to upgrading its Ripollet plant, also based near the Catalan capital. In fact, Barcelona is one of the main hubs in Europe in the car industry, with several manufacturing companies building vehicles and components.

The telecommunications company Cronos Group, based in Hong Kong, is opening its European offices in Barcelona to offer services throughout the continent and worlwide. According to the Catalan Ministry of Business and Employment, the company is expected to create 25 new jobs in the first year operating from the Catalan capital. Currently 10 people are already working in Cronos’ Barcelona offices. The project received the assistance of the Catalan Government’s programme ‘Invest in Catalonia’, which focuses on attracting foreign investment and international business. Cronos’s Managers explained they have decided to settle in Barcelona because it had become the world capital of the mobile phone and of telecommunications, since each year it organises the main international event in this sector. Furthermore, Cronos Group praised the talent and skills of Catalan workers.

Catalan pharmaceutical company Grífols has purchased 21.3% of Belgian biotech company TiGenix for €12 million through the subscription of a capital increase. TiGenix is a leading company in the field of cell therapy. The agreement settled on the appointment of two Grífols Members on TiGenix’s Board and a preferential right to negotiate the development and commercialization of all TiGenix products, with the only exception of advanced-medicinal product ChondroCelect. Earlier this month, Grífols had already strengthened its therapeutic arsenal by buying part of the Diagnostics unit of Swiss multinational Novartis for $1,675 million.

Car manufacturer SEAT, based in Martorell (Greater Barcelona), has set up 53,000 solar panels on the roof of its main factory and on top of parking spaces. The company has just completed the third stage of a €35 million project, which started in 2010, and occupies 10% of the 3 million square metres of its Martorell facilities. The solar panels occupy an extension equivalent to 40 soccer fields and can generate 15 million kWh of clean energy per year. This is equivalent to 25% of the energy needed to produce the Seat Leon or to the “annual consumption of 3,500 households”, said President Jürgen Stackmann. With this eco-friendly project Martorell is now the automation factory with the largest solar plant in the world. Furthermore, the panels were installed over existing facilities and do not occupy additional space.

The Catalan pharmaceutical company Grífols, based in Greater Barcelona, has bought part of the diagnostics unit of Swiss multinational Novartis for $1,675 million. Grífols has acquired products and ‘in vitro’ technology applied to diagnoses in the fields of blood transfusion and immunology, along with a production plant in California and offices in the US, Switzerland and Hong Kong. With the acquisition, the Grífols Diagnostic Division will represent $1 billion, 20% of the Catalan group’s total revenues. Grífols is the world’s third largest company in the production of blood-plasma derivatives. In the first half of 2013, Grífols registered a profit of €182.2 million, an increase of 36.9% on the same period of 2012.

The Catalan pharmaceutical company posted a net profit of €182.2 million between January and June 2013, which represents an increase of 36.9% on the same period of 2012. 92.1% of Grífols sales are made abroad and this figure has reached €1.27 billion, up from 6.2% on the first half of last year. Total turnover stood at €1.38 billion, a 4.9% increase. Furthermore, between April and June, the multinational based in Greater Barcelona obtained its highest ever quarterly sales in absolute terms, which reached €697.1 million and represented a 7.2% increase on the same period of 2012. Last year, Grífols bought out its main competitor in the US, Telecaris, which made the Catalan company one of the main pharmaceutical companies in North America, particularly in the blood-derivate products.